All Stories

  1. Interventions to prevent spontaneous preterm birth in women with singleton pregnancy who are at high risk: systematic review and network meta-analysis
  2. Which children and young people are at higher risk of severe disease and death after hospitalisation with SARS-CoV-2 infection in children and young people: A systematic review and individual patient meta-analysis
  3. Testing times: the association of intolerance of uncertainty and metacognitive beliefs to test anxiety in college students
  4. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs
  5. Care After Presenting with Seizures (CAPS): An analysis of the impact of a seizure referral pathway and nurse support on neurology referral rates for patients admitted with a seizure
  6. Practical Considerations and Challenges When Conducting an Meta-Analysis
  7. Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open‐Label, Randomized, Bayesian Noninferiority Trial
  8. Which children and young people are at higher risk of severe disease and death after SARS-CoV-2 infection: a systematic review and individual patient meta-analysis
  9. Using routinely recorded data in a UK RCT: a comparison to standard prospective data collection methods
  10. Developing a topic-based repository of clinical trial individual patient data: experiences and lessons learned from a pilot project
  11. Realising the full potential of data-enabled trials in the UK: a call for action
  12. Protocol for individual participant data meta-analysis of randomised controlled trials of patients with psychosis to investigate treatment effect modifiers for CBT versus treatment as usual or other psychosocial interventions
  13. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial
  14. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial
  15. EstablishINg the best STEp-up treatments for children with uncontrolled asthma despite INhaled corticosteroids (EINSTEIN): protocol for a systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data (IPD)
  16. Prognostic Indicators and Outcomes of Hospitalised COVID-19 Patients with Neurological Disease: A Systematic Review and Individual Patient Data Meta-Analysis
  17. Key stakeholders’ perspectives and experiences with defining, identifying and displaying gaps in health research: a qualitative study
  18. Seizure first aid training for people with epilepsy attending emergency departments and their significant others: the SAFE intervention and feasibility RCT
  19. Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II)
  20. The questionable efficacy of manualized psychological treatments for distressed breast cancer patients: An individual patient data meta-analysis
  21. Vigabatrin add-on therapy for drug-resistant focal epilepsy
  22. Determining the effectiveness of fibrin sealants in reducing complications in patients undergoing lateral neck dissection (DEFeND): study protocol for a randomised external pilot trial
  23. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia
  24. Seizure First Aid Training For people with Epilepsy (SAFE) frequently attending emergency departments and their significant others: results of a UK multi-centre randomised controlled pilot trial
  25. A guide on meta-analysis of time-to-event outcomes using aggregate data in vascular and endovascular surgery
  26. Ketogenic diets as an adjuvant therapy for glioblastoma (KEATING): a randomized, mixed methods, feasibility study
  27. Protocol for a systematic review of prognostic models for recurrent events in chronic conditions
  28. Individual participant data meta‐analysis of intervention studies with time‐to‐event outcomes: A review of the methodology and an applied example
  29. Individualised prediction of psychosis in individuals meeting at-risk mental state (ARMS) criteria: protocol for a systematic review of clinical prediction models
  30. Key stakeholders’ perspectives and experiences with defining, identifying and displaying gaps in health research: a qualitative study protocol
  31. Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review
  32. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
  33. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
  34. A scoping review describes methods used to identify, prioritize and display gaps in health research
  35. Core Health Outcomes in Childhood Epilepsy (CHOICE): Development of a core outcome set using systematic review methods and a Delphi survey consensus
  36. The efficacy of interventions for test-anxious university students: A meta-analysis of randomized controlled trials
  37. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
  38. Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
  39. Pharmacological management of post-traumatic seizures in adults: current practice patterns in the UK and the Republic of Ireland
  40. Investigation of one-stage meta-analysis methods for joint longitudinal and time-to-event data through simulation and real data application
  41. Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
  42. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
  43. A systematic review of the quality of randomized controlled trials of psychological treatments for emotional distress in breast cancer
  44. The Modified Ketogenic Diet in Adults with Glioblastoma: An Evaluation of Feasibility and Deliverability within the National Health Service
  45. The role of ketogenic diets in the therapeutic management of adult and paediatric gliomas: a systematic review
  46. Correction to: joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis
  47. Training health professionals to recruit into challenging randomized controlled trials improved confidence: the development of the QuinteT randomized controlled trial recruitment training intervention
  48. Graphs of study contributions and covariate distributions for network meta-regression
  49. Breakthrough seizures—Further analysis of the Standard versus New Antiepileptic Drugs (SANAD) study
  50. Investigation of 2-stage meta-analysis methods for joint longitudinal and time-to-event data through simulation and real data application
  51. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data
  52. Sharing and reuse of individual participant data from clinical trials: principles and recommendations
  53. Core Health Outcomes In Childhood Epilepsy (CHOICE): protocol for the selection of a core outcome set
  54. Ketogenic diets as an adjuvant therapy in glioblastoma (the KEATING trial): study protocol for a randomised pilot study
  55. The modified ketogenic diet for adults with refractory epilepsy: An evaluation of a set up service
  56. Network meta-analysis including treatment by covariate interactions: Consistency can vary across covariate values
  57. Resource implications of preparing individual participant data from a clinical trial to share with external researchers
  58. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data
  59. Exploring changes over time and characteristics associated with data retrieval across individual participant data meta-analyses: systematic review
  60. Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov
  61. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
  62. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
  63. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
  64. Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis
  65. One-stage individual participant data meta-analysis models: estimation of treatment-covariate interactions must avoid ecological bias by separating out within-trial and across-trial information
  66. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
  67. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
  68. Individual participant data meta-analyses compared with meta-analyses based on aggregate data
  69. Best practice for analysis of shared clinical trial data
  70. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures: an individual participant data review
  71. Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trials
  72. Long-Term Outcome Following Tracheostomy in Critical Care
  73. Inhibitory control training for appetitive behaviour change: A meta-analytic investigation of mechanisms of action and moderators of effectiveness
  74. UK publicly funded Clinical Trials Units supported a controlled access approach to share individual participant data but highlighted concerns
  75. Advertising as a cue to consume: a systematic review and meta-analysis of the effects of acute exposure to unhealthy food and nonalcoholic beverage advertising on intake in children and adults
  76. A systematic review of placebo-controlled trials of topiramate: How useful is a multiple-indications review for evaluating the adverse events of an antiepileptic drug?
  77. Interventions in randomised controlled trials in surgery: issues to consider during trial design
  78. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
  79. Assessment of the quality of harms reporting in non-randomised studies and randomised controlled studies of topiramate for the treatment of epilepsy using CONSORT criteria
  80. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
  81. Individual Participant Data (IPD) Meta-analyses of Randomised Controlled Trials: Guidance on Their Use
  82. Exploring Treatment by Covariate Interactions Using Subgroup Analysis and Meta-Regression in Cochrane Reviews: A Review of Recent Practice
  83. The CONSENSUS Study: Preliminary results of a mixed methods study to develop a core outcome set for late phase clinical trials in Oropharyngeal Cancer
  84. Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data
  85. Surgical trials in head and neck oncology: Renaissance and revolution?
  86. Elicitation of Expert Prior Opinion: Application to the MYPAN Trial in Childhood Polyarteritis Nodosa
  87. Quality-of-life outcomes of initiating treatment with standard and newer antiepileptic drugs in adults with new-onset epilepsy: Findings from the SANAD trial
  88. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov
  89. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
  90. Interventions to improve recruitment and retention in clinical trials: a survey and workshop to assess current practice and future priorities
  91. Treatment outcome after failure of a first antiepileptic drug
  92. External Validation of a Prognostic Model for Seizure Recurrence Following a First Unprovoked Seizure and Implications for Driving
  93. Sharing Individual Participant Data from Clinical Trials: An Opinion Survey Regarding the Establishment of a Central Repository
  94. A systematic review and meta-analysis examining the effect of eating rate on energy intake and hunger
  95. The CONSENSUS study: protocol for a mixed methods study to establish which outcomes should be included in a core outcome set for oropharyngeal cancer
  96. Risk-proportionate clinical trial monitoring: an example approach from a non-commercial trials unit
  97. Methodology of clinical trials for rare diseases
  98. The trials methodological research agenda: results from a priority setting exercise
  99. Time to 12-month remission and treatment failure for generalised and unclassified epilepsy
  100. Clinical trials in rare diseases: a review of practice
  101. External validation of a prognostic index
  102. The consensus studysquamous cell carcinoma of the oropharynx: late phase clinical trials; core outcomes
  103. The use of historical priors to improve the efficiency of phase II clinical trials with time-to-event endpoints
  104. Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension
  105. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures
  106. Assessing key assumptions of network meta-analysis: a review of methods
  107. Oxcarbazepine versus phenytoin monotherapy for epilepsy
  108. Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences
  109. Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures
  110. Barriers to recruitment for surgical trials in head and neck oncology: a survey of trial investigators
  111. The Value of Source Data Verification in a Cancer Clinical Trial
  112. Combining individual patient data and aggregate data in mixed treatment comparison meta-analysis: Individual patient data may be beneficial if only for a subset of trials
  113. Assessing the consistency assumption by exploring treatment by covariate interactions in mixed treatment comparison meta-analysis: individual patient-level covariates versus aggregate trial-level covariates
  114. Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial
  115. Anti-epileptic drug harms: issues for meta-analysis
  116. Feasibility of establishing a central repository for the individual participant data from research studies
  117. Individual participant data meta-analyses compared with meta-analyses based on aggregate data
  118. Simulation study - handling missing covariates in the context of external validation
  119. Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms
  120. Seizure recurrence after antiepileptic drug withdrawal and the implications for driving: further results from the MRC Antiepileptic Drug Withdrawal Study and a systematic review
  121. Indirect Comparisons: A Review of Reporting and Methodological Quality
  122. A Systematic Review of p53 as a Prognostic Factor of Survival in Squamous Cell Carcinoma of the Four Main Anatomical Subsites of the Head and Neck
  123. Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
  124. Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma
  125. Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison
  126. A comparison of methods for fixed effects meta-analysis of individual patient data with time to event outcomes
  127. Multiple treatment comparisons in epilepsy monotherapy trials
  128. Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
  129. Importance of competing risks in the analysis of anti-epileptic drug failure
  130. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial
  131. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial
  132. Emergency department use of a continuous femoral nerve block for pain relief for fractured femur in children
  133. Comment on “Adjuvant Therapy in Pancreatic Cancer: A Critical Appraisal”
  134. Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis
  135. An overview of methods and empirical comparison of aggregate data and individual patient data results for investigating heterogeneity in meta-analysis of time-to-event outcomes
  136. Individual patient data meta-analysis : Cervical stitch (cerclage) for preventing pregnancy loss in women
  137. Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes
  138. Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures
  139. Aggregate data meta-analysis with time-to-event outcomes